The Technical Analyst
Kaleido Biosciences, Inc. [KLDO]
Exchange: Other OTC Sector: Healthcare Industry: Biotechnology
Kaleido Biosciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0001
/ 18 apr 2024 @ 12:19
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.0043 mill |
| EPS: | -2.16 |
| P/E: | 0 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 42.62 mill |
| Avg Daily Volume: | 0.0027 mill |
| RATING 2024-03-04 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | n/a | n/a | n/a | n/a | n/a | |
| Asset | n/a | n/a | n/a | n/a | n/a | |
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0001 - 0.0001 ( +/- 0.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-02-28 | Van Hylckama Vlieg Johan | Sell | 2 087 | Restricted Stock Units |
| 2022-02-28 | Korn Jerald | Sell | 2 046 | Restricted Stock Units |
| 2022-01-14 | Van Hylckama Vlieg Johan | Buy | 350 000 | Restricted Stock Units |
| 2022-01-14 | Long Alison S | Buy | 125 000 | Restricted Stock Units |
| 2022-01-14 | Long Alison S | Buy | 46 800 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 0.00 |
| Last 92 transactions |
| Buy: 19 833 282 | Sell: 14 886 616 |
Forecast:
13:59 - $0
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0001 (0.00% ) |
| Volume | 0.0009 mill |
| Avg. Vol. | 0.0027 mill |
| % of Avg. Vol | 35.18 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KLDO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
KLDO
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Latest Press Releases
2022-01-21 11:04:00 - Press Release
Kaleido Biosciences To Present Updated Data Of Kb295 In Ulcerative Colitis At The 2022 Crohn's And Colitis Congress
Lexington, mass., jan. 21, 2022 (globe newswire) -- kaleido biosciences, inc. (nasdaq: kldo), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that the topline data obtained with kb295, a novel microbiome metabolic therapy (mmt™), in mild-to-moderate ulcerative colitis (uc), will be presented virtually at the 2022 crohn's and colitis congress.
2021-10-12 07:30:00 - Press Release
Kaleido Biosciences To Participate In The Jefferies Virtual Next Generation Ibd Therapeutics Summit
Lexington, mass., oct. 12, 2021 (globe newswire) -- kaleido biosciences, inc. (nasdaq: kldo), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that ceo dan menichella will present a company overview at the jefferies virtual next generation ibd therapeutics summit at 1:45pm et on tuesday, october 19.
2021-09-29 07:30:00 - Press Release
Kaleido Biosciences To Host Virtual R&d Presentation To Discuss Clinical Data And Pipeline Advancement On October 5, 2021
Latest data and clinical development plans for kb295 in ulcerative colitis (uc) to be presented
2021-09-02 07:30:00 - Press Release
Kaleido Biosciences To Participate In The Morgan Stanley 19th Annual Virtual Global Healthcare Conference
Lexington, mass., sept. 02, 2021 (globe newswire) -- kaleido biosciences, inc. (nasdaq: kldo), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that ceo dan menichella will participate in a fireside chat at the morgan stanley 19th annual virtual global healthcare conference at 2:45pm et on thursday, september 9.
2021-08-11 07:30:00 - Press Release
Kaleido Biosciences Reports Second Quarter 2021 Financial Results
--on track to report topline data from a clinical study of kb295 in patients with mild-to-moderate ulcerative colitis by end of third quarter-- --kaleido and the copd foundation to collaborate on the development of kb109 in patients with copd; plan to initiate phase 2 clinical study in first quarter 2022--
Latest News
2022-04-14 09:30:01 - PennyStocks
Best Penny Stocks to Buy? 3 to Watch as Musk Offers $43B for TWTR
Check these three penny stocks out as Musk tries to buy TWTR The post Best Penny Stocks to Buy? 3 to Watch as Musk Offers $43B for TWTR appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-04-13 12:05:33 - InvestorPlace
Dear KLDO Stock Fans, Mark Your Calendars for April 28
Kaleido Biosciences (KLDO) stock is soaring on Wednesday but anyone considering a stake in the company will want to keep an eye on April 28. The post Dear KLDO Stock Fans, Mark Your Calendars for April 28 appeared first on InvestorPlace.
2022-04-13 09:28:08 - PennyStocks
Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes
Here's what you need to know about trading penny stocks on April 13th The post Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-04-08 12:27:02 - Benzinga
Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why
Kaleido Biosciences Inc (NASDAQ: KLDO) has delivered formal notice to voluntarily delist its common stock from NASDAQ as the Company will stop all operations. The Company expects to file a Form 25 with the Securities and Exchange Commission by April 18 to effect the voluntary delisting.
2022-03-23 12:47:14 - Zacks Investment Research
ORIC Stock Plunges on Discontinuation of Oncology Candidate
ORIC declines on discontinuation of pipeline candidate ORIC-101 following planned interim analyses of two phase Ib studies.
2022-02-04 11:29:18 - Zacks Investment Research
Here's Why Kaleido Biosciences, Inc. (KLDO) is Poised for a Turnaround After Losing 33.2% in 4 Weeks
Kaleido Biosciences, Inc. (KLDO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2022-01-21 11:04:00 - GlobeNewsWire
Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress
LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that the topline data obtained with KB295, a novel Microbiome Metabolic Therapy (MMT™), in mild-to-moderate ulcerative colitis (UC), will be presented virtually at the 2022 Crohn's and Colitis Congress.
2022-01-05 08:28:09 - Zacks Investment Research
Kaleido Biosciences, Inc. (KLDO) Sees Hammer Chart Pattern: Time to Buy?
Kaleido Biosciences, Inc. (KLDO) recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
2021-11-01 10:43:12 - Zacks Investment Research
Here's Why Kaleido Biosciences, Inc. (KLDO) Is a Great 'Buy the Bottom' Stock Now
Kaleido Biosciences, Inc. (KLDO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
2021-11-01 09:57:14 - Zacks Investment Research
Kaleido Biosciences, Inc. (KLDO) Reports Q3 Loss, Misses Revenue Estimates
Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 1.82% and -58.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?